Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Despite innovative pipeline assets, Regeneron's stock recovery above $1,000 is unlikely due to Eylea's revenue decline and lack of blockbuster drugs. The Pharma is fairly priced today, in my view.

Drug developer Regeneron Pharmaceuticals Inc. purchased the Pitney Bowes Inc. building at 1 Global View in Rensselaer Technology Park for $17.75 million, Pyramid Brokerage broker Peter Struzzi ...

“This major collaboration with Roche provides important scale and global expertise to bring REGN-COV2 to many more patients in the United States and around the globe.” Regeneron and Roche will ...

The synthetic DNA weaver Twist Bioscience has teamed up with Regeneron to deliver a custom next-generation sequencing test that can track minute genetic differences among global populations.

JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today a global 1 agreement to ...